Exactly look at the updated pipeline slide if lympro revenues are what Jason predicted then I see a major problem bc a possible partner for elto I'm 2016 is the next non dilutive funding I see. I feel Gerald has definitely shyed away from his previous statements of what lympro is (first to market and gold standard) The fact our only analyst predicted such low revenue in upcoming years and it wasn't addressed during cc weeks before "launch" cmon ppl you can't turn a blind eye here?? Lympros launch should be the most exciting thing right now and main focal point.